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Proteinase-Activated Receptors 1 and 2 Regulate
Invasive Behavior of Human Melanoma Cells via
Activation of Protein Kinase D1
Cordula Kempkes1,2,8, Anke Rattenholl1,3,8, Jo¨rg Buddenkotte1, Elwira Strozyk4,5, Ju¨rgen Eberle6,
Angelika Hausser7, Ferda Cevikbas2, Stefan W. Schneider4 and Martin Steinhoff2
Recent studies have indicated an important role of proteinases and proteinase-activated receptors (PARs) in
tumorigenesis. Although a role for PARs has been described in various skin tumors including melanoma, the
underlying cellular mechanisms have not been understood. Recent studies have suggested PAR1 as a regulator
of melanoma cell growth and metastasis by affecting angiogenic and invasive factors. Moreover, changes in
the expression patterns of PAR1 and PAR2 correlate with skin cancer progression, and PAR1 is overexpressed
in melanoma. Therefore, we sought to elucidate the putative role of PAR1- and PAR2-mediated signal
transduction pathways during melanoma progression. Activation of both PAR1 and PAR2 led to rapid
phosphorylation of protein kinase D1 (PKD1) in cultured WM9 melanoma cells. PKD1 is known to be involved
in cell migration, integrin regulation, and intracellular vesicle transport. Downregulation of PKD1 by siRNA
resulted in diminished proliferation, decreased avb3 integrin regulation, and secretion of pro-angiogenic
chemokine IL-8 in WM9 cells. In conclusion, our results show that PAR1 and PAR2 are involved in WM9 cell
proliferation and secretion of IL-8 by activation of PKD1. Inactivation of the PKD1 pathway may be beneficial
for the inhibition of PAR-induced melanoma proliferation and for maintenance of the inflammatory tumor
environment.
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INTRODUCTION
Proteinase-activated receptors (PARs) are G-protein-coupled
receptors with seven transmembrane domains that are stimu-
lated by a unique activation mechanism. The extracellular N-
terminus is specifically cleaved by certain serine proteinases
(e.g., thrombin, trypsin, tryptase, cathepsin G), exposing a
formerly cryptic peptide sequence of six amino acids.
Subsequently, this ‘‘tethered ligand’’ can bind to the second
extracellular loop of PARs, leading to the induction of specific
intracellular cell signaling events, which can also be mimicked
by stimulating PARs with synthetic peptides of the tethered
ligand sequence. PARs are expressed in numerous tissues that
exert several biological effects, including cell proliferation,
inflammation, and blood coagulation. In addition, both PAR1
and PAR2 expressions are abundantly upregulated in tumors of
various tissues (Tellez and Bar-Eli, 2003; Steinhoff et al., 2005;
Melnikova et al., 2008). Semiquantitative RT-PCR revealed that
PAR1, but not PAR2, is expressed by primary melanocytes of
both newborn and adult origin. Nevertheless, PAR2 on
keratinocytes is essential for melanosome transfer between
melanocytes and keratinocytes (Seiberg et al., 2000).
The incidence of malignant melanoma is still increasing
and causes most deaths related to skin cancer (Bowden,
2004; Larson et al., 2009). PAR1 was reported to be
significantly overexpressed in malignant melanomas (Tellez
et al., 2003; Melnikova et al., 2008; Tellez and Bar-Eli, 2003;
Villares et al., 2009) and PAR2 immunoreactivity was found
to be upregulated both in nevi and malignant melanomas
(Massi et al., 2005). Thrombin-induced activation of PAR1 on
murine melanoma cells led to increased tumor growth and
enhanced pulmonary metastasis in vivo (Nierodzik et al.,
1992; Nierodzik et al., 1998). In vitro overexpression of
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PAR1 in a nonmetastatic melanoma cell line (SB2) led to
increased adhesion to extracellular matrix molecules and also
modulated cytoskeletal reorganization (Nierodzik et al.,
1998). Furthermore, activation of PAR1 induced the recruit-
ment of avb5 integrin to focal contact sites (Hazarika et al.,
2004).
PAR1 expression is controlled by the transcription factor
activator protein-2a, and loss of activator protein-2a causes
overexpression of PAR1, which correlates with increased
metastatic potential (Tellez et al., 2003). Accordingly,
thrombin-induced activation of PAR1 on M24met melanoma
cells enhanced their migration and metastasis. Interestingly,
thrombin coactivated PAR2 in these cells by an indirect
cleavage-independent mechanism, indicating that PAR2 may
have an additional, possibly collaborative role in melanoma
metastasis. In fact, treatment of melanoma cells with a
selective PAR2 agonist also enhanced experimentally in-
duced metastasis (Even-Ram et al., 2001). Finally, increased
expression of PAR1 in malignant melanomas was recently
correlated with increased expression of IL-8 and integrins
(Shi et al., 2004).
Activated PARs induce production of diacylglycerol, an
important second messenger in cells of which the primary
cellular targets are protein kinase C (PKC) kinases, leading to
their translocation to the plasma membrane and subsequent
phosphorylation of various molecules. Thus, the family of
protein kinase D (PKD) kinases is a direct substrate of PKCs.
The PKD family of serine/threonine PKs comprises three
members: PKD1 (PKCm), PKD2, and PKD3 (PKCn). PKD1 has
important roles in cell migration and invasion. This kinase
reportedly arranges cell motility by aiding the transport of
avb3 integrin to emerging focal adhesions (Tellez et al.,
2007). Moreover, PKD1 was found to be directly involved in
tumor cell invasion and metastasis, and it promotes pro-
proliferative and anti-apoptotic effects (Tellez et al., 2007).
Here, we provide early evidence that both PAR1 and PAR2
can activate PKD1 in malignant melanoma cells, thereby
enhancing cell proliferation and motility.
RESULTS
Stimulation of PAR1/PAR2 on WM9 cells leads to
phosphorylation of PKD1
WM9 melanoma cells respond with a fast [Ca2þ ]i signal to
synthetic PAR agonists (Figure 1a). As both PAR1 and PAR2
are known to be involved in melanoma invasion and
metastasis, we searched for possible signal transduction
molecules after PAR stimulation in melanoma cells. Both
PAR1 and PAR2 agonists led to a rapid phosphorylation of
PKD1 within 5minutes after stimulation (Figure 1b). Immu-
noblot analysis using a specific antibody against phospho-
Ser916-PKD1 gave an immunoreactive band of about
110 kDa, which corresponds to the molecular mass of
PKD1. Activation started to fade 30minutes after stimulating
peptides were added. However, PKD1 remained partly
phosphorylated even after 4 hours. We confirmed this
observation by immunofluorescence: in unstimulated WM9
cells no phospho-PKD1 was detectable, whereas in PAR-
agonist-stimulated WM9 cells, phospho-PKD1 was detected
in intracellular compartments, which appeared to be partly
aligned along cytoskeletal fiber structures (Figure 1c).
Unstimulated WM9 cells did not show a positive staining
for phospho-Ser916-PKD1, unless the cells were in a mitotic
state (Figure 1d).
Knockdown of PKD1 in WM9 melanoma cells
We investigated the role of PKD1 in invasiveness and
metastasis of melanoma cells by using RNA interference for
PKD1-specific knockdown. For high RNA interference
efficiency, WM9 cells were transfected with pSuppressor
construct with or without a short interfering RNA specific for
PKD1, and cells were selected with the antibiotic G418 for
14 days. Stable cell clones were screened for their ability
to silence PKD1 expression by real-time PCR analysis
(Figure 2a). In all stable clones, the PKD1 mRNA level was
reduced by at least 80% as compared with untransfected
WM9 cells, which was confirmed by immunoblot analysis
(Figure 2b). The slightly decreased expression of PKD1 in
mock-transfected WM9 cells was not significant (Figure 2b).
The maintenance of PKD1 suppression was monitored for
each experiment (Livak and Schmittgen, 2001).
Stable PKD1 antisense clones exhibit diminished proliferation
Recently, PKD1 has been reported to be involved in the
proliferation of a pancreatic carcinoma cell line (Guha et al.,
2002). We elucidated the impact of PKD1 on the proliferation
of WM9 cells. First, we compared the capability of cell
proliferation of normal (untransfected) WM9 cells and PKD1
antisense-expressing cells by means of a 3[H]-thymidin
incorporation assay. Normal WM9 cells, as well as
mock-transfected WM9 cells, revealed high 3[H]-thymidin
incorporation levels, whereas WM9 cells with low PKD1
expression showed significantly diminished proliferation with
a lower 3[H]-thymidin incorporation level (Figure 3a).
Activation of PARs on melanoma cells was recently
reported to increase proliferation (Even-Ram et al., 2001).
Therefore, we analyzed the proliferation capacities of
untransfected WM9 cells after stimulation with PAR1- or
PAR2-activating peptides. Interestingly, we found that stimu-
lation of PAR1 or PAR2 on WM9 cells had no obvious effect
on cell proliferation (Figure 3b). This could be explained by
the possibility that proliferation of WM9 cells was already at a
maximum. Kinase protein analyses showed a constitutive
activation of ERK1/2 kinases in unstimulated WM9 cells (data
not shown). The constitutive activation of ERK1/2 could
account for a sustained cell proliferation, which was affected
by neither PAR1 nor PAR2 activation in these cells (Satya-
moorthy et al., 2003). WM9 cells are highly proliferative but
do not display an invasive phenotype, because of which we
failed to establish migration assays using Boyden Chamber,
wound closure experiments, or time-lapse microscopy.
Knockdown of PKD1 in WM9 cells affects PAR1-mediated
secretion of IL-8
Both PAR1 and PAR2 are known to stimulate the secretion of
IL-8 in endothelial and epithelial cells, as well as in
fibroblasts (Amadesi et al., 2009). In addition, IL-8 is known
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Figure 1. Stimulation of proteinase-activated receptor (PAR)1 and PAR2 induces phosphorylation of protein kinase D (PKD)1. Incubation with PAR1- and
PAR2-activating peptides (activating peptide for PAR1 (AP1), activating peptide for PAR2 (AP2); 0.1mM) induces fast activation of PKD1. (a) Stimulation with AP1
and AP2 induces increase of [Ca2þ ]i in WM9 cells. (b) AP1- or AP2-induced phosphorylation of PKD1 (110 kDa) peaked after 5minutes, decreased rapidly
within 15minutes, but lasted up to 4 hours in WM9 cells. (c) Immunoreactivities of phospho-Ser916-PKD1 and b-actin were localized in WM9 cells after
15minutes of stimulation with AP1 or AP2 (0.1mM). Only agonist-induced phosphorylation of PKD1 was detectable, which was localized in vesicular
compartments in the cells. However, there was no costaining with b-actin fibers. (d) Unstimulated cells only showed positive staining for phospho-Ser916-PKD1
during mitosis (bar¼10 mm).
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to promote progression of prostate cancer and melanoma
(Huang et al., 2002; Araki et al., 2007). Thus, we analyzed
the role of PAR1 and PAR2, as well as that of PKD1, for IL-8
secretion of WM9 cells. Only PAR1 significantly increased
the moderate baseline of IL-8 secretion (216±34% compared
with 100±20% of unstimulated cells), whereas PAR2 did not
significantly affect IL-8 secretion (135±29%; Figure 4a).
Conversely, IL-8 secretion was markedly inhibited in PKD1-
knockdown cells down to 3±1.5% (Figure 4b), and
stimulation of PAR1 did not increase IL-8 secretion in these
cells (Figure 4c). We cannot exclude the possibility that the
transfection and selection conditions influenced the secretion
of IL-8, because the mock-transfected WM9 cells presented
a nonsignificant reduced secretion of IL-8 (63±29%).
Together, these results suggest that PAR1-mediated mela-
noma progression involves the induced secretion of IL-8 by
PAR1. This mechanism is partly mediated by PKD1, because
the loss of PKD1 expression results in a significant decrease in
IL-8 secretion.
Knockdown of PKD1 in WM9 cells leads to changes in cell
shape and morphology
Immunofluorescence analysis revealed that unstimulated
WM9 cells contained a large amount of b-actin at the cell
rims. PAR1 and PAR2 activation provoked rapid formations of
b-actin-positive stress fibers (Figure 5). These fibers were still
present after 2 hours. Unstimulated PKD1-knockdown mela-
noma cells also showed predominant immunoreactivity for
b-actin along the cell rim with some cytoskeletal fibers that
contained b-actin. However, these cells revealed much less
b-actin-containing filopodia. After stimulation of either PAR1
or PAR2, some stress fibers had formed in the cell cytosol, and
filopodia formation was sparse. Nevertheless, no major
changes in b-actin redistribution were observed.
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Figure 2. Protein kinase D (PKD)1 downregulation in WM9 cells by selective
knockdown. PKD1 expression analysis of either normal or PKD1-knockdown
WM9 cells. (a) PKD1-knockdown cells present a significant decrease of PKD1
expression in real-time PCR. However, control-transfected cells present a
nonsignificant decreased expression of PKD1. Triplicate observation in n¼ 3
experiments; data are presented as means±SEM, and differences between
data were tested by Student’s t-test for unpaired data. **Po0.005. (b) Short
interfering RNA to PKD1 led to a significant reduction of protein translation
in PKD1-knockdown cells (lane 3). Although transcription of PKD1 was
decreased in mock cells (lane 2), translation of the PKD1 protein is
comparable to that of untransfected WM9 (lane 1) cells.
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Figure 3. Proliferation is compromised in protein kinase D (PKD)1-
knockdown melanoma cells. (a) Proliferation of normal, mock-transfected,
and PKD1-knockdown WM9 cells was determined by [3H]-thymidine
incorporation. Stably transfected PKD1-knockdown WM9 cells display an
80% inhibition of cell proliferation as compared with nontransfected and
mock-transfected WM9 cells. Data are presented as means±SEM.
Differences between data were tested by Student’s t-tests for unpaired data.
**Po0.005. (b) Stimulation of either proteinase-activated receptor (PAR)1 or
PAR2 (0.1mM agonists) had no effect on WM9 cell proliferation. The data
shown are n¼3 and presented as means±SEM.
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Knockdown of PKD1 in WM9 cells affects integrin avb3
distribution
For normal cell migration, integrins (heterodimeric cell
adhesion receptors consisting of alpha and beta subunits)
are indispensable. Proper function involves a controlled
cycling of the integrin receptors between the cell surface and
cytosol. Thus, it is not surprising that several integrins are
known to have a direct role in tumor progression. For
example, integrin avb3 participates in tumor-induced angio-
genesis and metastasis (Kumar et al., 2001; Nemeth et al.,
2007; Neto et al., 2007). Integrin avb3 binds to vitronectin,
fibronectin, laminins, matrix-metalloproteinase-2, fibrinogen,
prothrombin, thrombospondin, and von-Willebrand factor.
Therefore, we analyzed the distribution of avb3 after PAR1
and PAR2 activation in wild type and siPKD1-transfected
WM9 cells. In unstimulated cells, avb3 was mainly found at
the cell surface. Fifteen minutes after PAR activation, avb3
was widely distributed in the cell; after 60minutes, avb3 was
back at the cell membrane (Figure 6a). The PKD1 knockdown
in WM9 cells led to a reduced staining of avb3 integrin on the
cell membrane (Figure 6b). However, PAR activation did not
lead to a visible change in integrin distribution in siPKD1-
transfected WM9 cells.
DISCUSSION
This study shows that the activation of both PAR1 and PAR2 in
the melanoma cell line WM9 leads to fast activation of PKD1,
a previously unreported member of the PKC family of kinases
involved in tumorigenesis. PKD1 is apparently an important
intracellular kinase, as its presence and its PAR1- and PAR2-
mediated activation are important for cell proliferation, avb3
integrin distribution, and secretion of inflammatory cytokines
such as IL-8.
PKD1 is important for cancer cell migration in myeloma
and breast cancer (Bowden et al., 1999; Qiang et al., 2004),
and activation of PKD1 prevents apoptosis in pancreatic
tumor cells (Trauzold et al., 2003). Pancreatic tumor cells
present an increased transcription of neurotensin receptor
type-1 during tumor progression (Wang et al., 2000).
Neurotensin receptor type-1 is a member of the heptahelical
G-protein-coupled receptor family, and activation of neuro-
tensin receptor type-1 resulted in rapid intracellular calcium
mobilization and PKC phosphorylation (Ryder et al., 2001),
properties that are also well known for both PAR1 and PAR2
(reviewed in Amadesi et al., 2009). Neurotensin receptor
type-1-mediated PKC activation further led to phosphoryla-
tion of PKD1 in the pancreatic tumor cell line PANC-1
(Huang et al., 2002). Recent data showed the direct
phosphorylation of PKD isoforms by agonist-activated PAR2
in dorsal root ganglia, indicating PKD1 to depict an important
component of a signal transduction pathway for proteinase-
induced activation of nociceptive neurons and inflammatory
responses (Amadesi et al., 2009). Therefore, we investigated
whether PKD1 contributes to PAR1- and/or PAR2-induced
modification of melanoma cell behavior.
PAR1 is known to be overexpressed in malignant
melanoma, and the expression of PAR1 is known to
contribute to melanoma cell invasion (Bromberg et al.,
2001; Tellez et al., 2003; Shi et al., 2004; Boire et al.,
2005; Goerge et al., 2006). Until now, the underlying
mechanisms of PAR1 activation and melanoma progression
have barely been understood. PAR1 is normally expressed by
thrombocytes, neutrophils, mast cells, granulocytes, endothe-
lial cells, fibroblasts, myocytes, neurons, and astrocytes.
PAR1 is upregulated during inflammation and triggers
degranulation of mast cells. It can be activated by various
serine proteinases such as thrombin, kallikreins, plasmin, and
cathepsin G, as well as by metalloproteinase-1, all of which
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Figure 4. IL-8 secretion is enhanced after proteinase-activated receptor
(PAR)1 stimulation and decreased after protein kinase D (PKD)1 knockdown
in cultured WM9 melanoma cells. (a) WM9 cells were stimulated with either
activating peptide for PAR1 (AP1) or activating peptide for PAR2 (AP2)
(0.1mM), and the secretion of IL-8 was determined by ELISA. Activation of
PAR1 induced enhanced IL-8 release in WM9 cells, whereas PAR2 did not
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stimulation with AP1 nor stimulation with AP2 increased IL-8 secretion
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means±SEM. Differences between data were tested by Student’s t-tests
for unpaired data. *Po0.05; **Po0.005.
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are involved in inflammation and tumorigenesis (Hollenberg
et al., 2008; Stefansson et al., 2008; Villares et al., 2009;
Wilson et al., 2009). Tumors are often called wounds that do
not heal because noticeable similarities exist, similar to
neovascularization and extracellular matrix deposition
(Dvorak, 1986; Chantrain et al., 2006). Therefore, we
investigated the activation and role of both PAR1 and PAR2
in WM9 melanoma cells. In normal skin, PAR2 is expressed
by keratinocytes, endothelial cells, fibroblasts, sensory nerve
fibers, and cells of the immune system (e.g., mast cells and
neutrophils). Our own data revealed upregulation of PAR2 in
these cells during inflammation (Shpacovitch et al., 2007).
Activation of PAR2 has an important role in diseases that
involve acute or chronic inflammation of the skin
(e.g., contact dermatitis and atopic dermatitis; Buddenkotte
et al., 2005; Grant et al., 2007). The expression of PAR2 in
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Figure 5. Knockdown of protein kinase D (PKD)1 in WM9 cells leads to changes in cell shape. Untransfected and PKD1-knockdown WM9 cells were
stimulated with activating peptide for proteinase-activated receptor (PAR)1 (AP1) or activating peptide for PAR2 (AP2) (0.1mM) for 120minutes and fixed,
and fiber formation was monitored with b-actin-FITC antibody. In normal, unstimulated WM9 cells, stress fibers did not form (a, d). When PAR1 (b, c)
and PAR2 (e, f) were activated, formation of stress fibers was significantly increased in WM9 cells. PKD1 knockdown induced marked changes in the
actin cytoskeleton structure (g–l). Unstimulated PKD1-knockdown cells display actin-positive fibers (g, j). Here, the activation of PAR1 and PAR2 in
PKD1-knockdown cells did not induce formation of stress fibers, and no changes to unstimulated cells were observed (h, i, k, l) (bar¼ 10mm).
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keratinocytes is also important for melanosome transfer and
skin tanning. Normal melanocytes do not express PAR2,
whereas nevi and malignant melanomas express PAR2 but
present no significant differences between benign and
malignant melanocytic lesions (Massi et al., 2005).
Others have shown that both PAR1 and PAR2 contribute to
melanoma cell metastasis. Interestingly, PAR2 can promote
metastasis by means of a thrombin-dependent mechanism.
However, the details of this mechanism remain elusive
(Even-Ram et al., 2001). We therefore analyzed possible
signal transduction pathways triggered in WM9 cells after
PAR1 or PAR2 activation. We found that either PAR1- or
PAR2-activating peptides temporarily induced the phosphor-
ylation of PKD1 at Ser916. We found phosphorylated PKD1
close to a-tubulin fibers during mitosis of WM9 cells. PKD1 is
known to have a role in the cell cycle (Rykx et al., 2003).
Indeed, we found that cell proliferation was significantly
downregulated in PKD1-silenced melanoma cells.
The immunofluorescence staining of activated PKD1 in
WM9 cells revealed that after PAR1 and PAR2 stimulation,
PKD1 was mainly found in structures that appeared to be
vesicle-like. It is appreciated that PKD1 is important for
vesicle transport from the trans-golgi network to the cell
surface and for recycling of internalized avb3 integrin
vesicles back to the cell membrane (Baron and Malhotra,
2002; Jaggi et al., 2007). Therefore, activation of PAR1 and
PAR2 could lead to a PKD1-dependent vesicle transport to the
cell membrane. However, we could not detect any coloca-
lization of PKD1-positive vesicles with either b-actin or
a-tubulin fibers.
Here, we also demonstrate that melanoma cells can
secrete the chemoattractive and proangiogenic molecule IL-8
after stimulation of PAR1. IL-8 expression by human
melanoma cells is known to correlate with their metastatic
capability in vivo (reviewed in Tellez et al., 2007). The
secretion of IL-8 is influenced by PKD1, as knockdown of
PKD1 led to a decrease in the baseline secretion of IL-8. A
reduced release of IL-8 could lead to a diminished invasion
and metastasis of melanoma (Bar-Eli, 1999). However, PAR1
stimulation in siPKD1-WM9 cells did not increase IL8-
secretion. Therefore, secretion of IL-8 in WM9 cells depends
only on PKD1 and could be independent from other signaling
pathways. PAR2 expression had no significant impact on IL-8
secretion, which could be explained by the lower PAR2
expression compared with PAR1 expression in these cells. We
hypothesize that PKD1 is involved in the secretion of pro-
inflammatory cytokines, which will be exocytosed from
tumor cells to establish a pro-inflammatory environment
and induce neovascularization.
Invasive tumor cells form membrane protrusions to come
in contact with extracellular matrix proteins. At these
invadopodia, metalloproteinases are secreted, which degrade
the extracellular matrix to enable tumor cell invasion (Mauch
et al., 1994; Schnaeker et al., 2004; Villares et al., 2008).
PKD1 is also enriched at invadopodias (White et al., 2007).
Thus, we asked whether filopodia formation might be
impaired in PKD1-silenced WM9 cells. In addition, non-
transfected cells contained numerous filopodia, whereas
WM9 cells expressing PKD1-antisense displayed a rounded
appearance with only sparse filopodia formation. The
WM9
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Figure 6. Protein kinase D (PKD)1 knockdown affects avb3-integrin distribution in WM9 cells. (a, b) Indirect immunofluorescence revealed fast internalization
of avb3-integrin after activating peptide for proteinase-activated receptor (PAR)1 (AP1) and activating peptide for PAR2 (AP2) stimulation in either WM9
or mock-transfected WM9 cells (0.1mM, 15minutes) and recycling of the integrin back to the cell membrane after 60minutes. (c) Staining for avb3-integrin
on the cell membrane in siPKD1-WM9 cells appears to be reduced, and the integrin is only found in clusters in filopodia-like structures. Stimulation with
AP1 and AP2 induced internalization, and recycling of avb3-integrin is reduced (bar¼ 10mm).
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cytoskeletal protein b-actin is abundant in filaments along the
cell rims, giving WM9 cells a wispy appearance. When either
PAR1 or PAR2 was activated, stress fiber formation was
pronounced in WM9 cells. In contrast, WM9 cells expressing
PKD1 antisense showed almost no filopodia positive for
b-actin. Moreover, PAR activation in these cells induced only
minor formation of actin stress fibers. These observations are
in accordance with a recent report demonstrating that active
PKD1 interacts with F-actin at the leading edge of migrating
cells, strongly suggesting a direct role of PKD1 in actin
remodeling (Eiseler et al., 2007).
PKD1 was shown to be indispensable for the fast recycling
of avb3 by antagonizing a5b1 recycling in NIH3T3
fibroblasts, thus enabling persistent migration of cells (Woods
et al., 2004; White et al., 2007). Integrin avb3 is highly
expressed in metastatic melanoma cells, and it contributes to
the malignant phenotype (Nemeth et al., 2007). Integrin
recycling to the cell surface is an important mechanism for
cell migration and invasion. Because we saw that PAR
agonists can induce a temporary phosphorylation of PKD1 at
Ser916 in WM9 cells, we wondered whether PAR activation
or silencing of PKD1 in WM9 cells would induce changes in
avb3 integrin distribution. Activation of either PAR1 or PAR2
induced a fast internalization of avb3 integrin from the cell
membrane and recycling of the integrin within 60minutes.
Therefore, activation of PAR1 or PAR2 in melanoma cells
could influence cell migration. However, we failed to present
this possible phenotype for WM9 cells in the Boyden
Chamber assay, wound closure experiments, and time-lapse
video microscopy because of a low migration phenotype of
the cell line. Knockdown of PKD1 in WM9 cells results in
lower cell membrane expression of avb3 integrin, and PAR
stimulation induced no obvious changes in avb3 distribution.
Our results maintain the important role of PKD1 for avb3
integrin recycling in tumor cells and hint that PAR-induced
activity of PKD1 could be important for avb3-dependent
migration of tumor cells. However, future studies with highly
invasive and migrating melanoma cell lines must be
conducted to improve this hypothesis.
In conclusion, we present early evidence that activation of
both PAR1 and PAR2 induces rapid and transient phosphor-
ylation of PKD1 in WM9 cells, serving as an in vitro model
system for studying the mechanisms of melanoma progres-
sion, remodeling, and metastasis. Further elucidation of the
signal transduction pathways involved in PAR-mediated
PKD1 activation may identify new targets for therapeutic
intervention in malignant melanoma.
MATERIALS AND METHODS
Materials
Reagents were purchased from the indicated providers: rabbit
polyclonal anti-PKD1 and anti-phospho-Ser916-PKD1 from Cell
Signalling (Boston, MA), mouse anti-avb3-antibody (clone LM609)
from Millipore (Billerica, MA), mouse anti-tubulin antibody (clone
DM1A) from Calbiochem (Darmstadt, Germany), Fura2AM and
FITC-conjugated anti-b-actin and secondary antibodies from Sigma-
Aldrich (Taufkirchen, Germany), [3H]-thymidine from GE Health-
care (Braunschweig, Germany), and activating peptides for PAR1 and
PAR2 from Bachem (Weil am Rhein, Germany). The PKD1-gene
silencing construct and pSuppressor plasmid were described
previously (Eiseler et al., 2007).
Cell lines
The human melanoma cell line WM9 was maintained in a standard
culture medium containing enriched Earle’s salts, nonessential
amino acids, glutamic acid, and 10% heat-inactivated fetal
calf serum (Biochrom, Berlin, Germany). Culture medium for
stably transfected PKD1-knockdown WM9 cells and mock-
transfected WM9 cells was supplemented with 150mgml1 G418
(Sigma-Aldrich, Taufkirchen, Germany). Cells were changed to
serum-free medium 24hours before the experiments (except for
proliferation assay).
Generation of transfected cells
WM9 cells were transfected using Lipofectamine 2000 (Invitrogen,
Carlsberg, Canada) with pSuppressor-PKD1 or control vectors. After
2 days the cells were cultured in standard culture medium supple-
mented with 400mgml1 G418 sulfate. The expression of PKD1 was
assessed by real-time PCR (forward: 50-TGCTGTGGGGGCTGGTA
CGT-30 and reverse: 50-GTGCGGATGGTGCTGACCCC-30; Livak and
Schmittgen 2001).
Calcium mobilization assay
The calcium mobilization assay was performed as described
elsewhere (Bocheva et al., 2009) with minor changes. WM9 cells
were incubated with 2.5 mM Fura-2AM for 60minutes in HEPES-
buffered Ringer solution and then washed and stimulated with PAR1
and PAR2 agonists (10
4
M).
Immunoblot analysis
WM9 cells were harvested after treating several times with hot lysis
buffer (100mM Tris (pH 6.8), 4% SDS, 0.2% bromophenol blue, 20%
glycerol, and 5% b-mercaptoethanol). Equal volume samples (20 ml)
were separated by denaturing SDS-PAGE and were transferred to
nitrocellulose membranes. Membranes were blocked with 5% milk
powder/1 phosphate-buffered salineþ Tween-20 and incubated
with specific antibodies against phosphorylated and unphosphory-
lated PKD1 and peroxidase-conjugated secondary antibodies. The
membranes were developed using the ECL Plus Western blotting
detection system (GE Healthcare).
Proliferation assay
For the proliferation assay, 150,000 cells per ml were cultured in 96-
well flat-bottom plates in a final volume of 200 ml. Simultaneously,
1mCi per well [3H]-thymidine was added for 48 hours and thymidine
incorporation was measured by liquid scintillation counting.
Immunofluorescence microscopy
Transfected and nontransfected WM9 cells were washed with cold
phosphate-buffered saline and then fixed and permeabilized for
30minutes in 1 phosphate-buffered saline/1% fetal calf serum/
0.05% saponin at 4 1C. Primary antibodies were detected with FITC-
conjugated antimouse IgG (1:250, 1 hour, room temperature). Cells
were embedded in Vectashield mounting medium (Vector, Burlin-
game, CA). Specimens were observed using a Bio-Rad MRC 1000
confocal microscope (Dreieich, Germany). Images were collected at
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0.68mm intervals using a Zeiss 100 Plan Apo 1.4 NA objective and a
zoom of  1.5–2 (Zeiss, Jena, Germany).
Statistical analysis
Microsoft Excel software was used to manage data and create
graphs. The mean data of the experiments are given in percent-
age±SD unless otherwise indicated. Statistical significance was
tested with unpaired Student’s t-test; significant differences of
compared values are indicated (Pp0.05).
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